Durgical
EN
Open the app

Toxicities of blood-cancer treatment by drug class

  • Treatment and support

Every cancer drug has a side effect that is predictable from how it works. Knowing each class's signature harm lets you prevent it or spot it early.

Updated

What it is

Drugs used for leukaemia, lymphoma and myeloma share some toxicities because they all attack dividing cells (marrow suppression, mucositis, hair loss, nausea, infertility), and each class adds its own signature harm to a particular organ. The harms are early (days to weeks: low counts, mucositis, tumour lysis), late (months: neuropathy, lung fibrosis) or very late (years: heart failure, second cancers). Regimens and doses are chosen by specialist teams and are not given here.

What to know

  • Shared by most cytotoxics: marrow nadir about 7–14 days after a cycle, mucositis, hair loss, nausea and vomiting, infertility, harm to a fetus and a later risk of second cancers.
  • Alkylating agents (cyclophosphamide, ifosfamide, melphalan, busulfan, bendamustine): haemorrhagic cystitis from acrolein (prevented with mesna and fluids), infertility, and second MDS or AML years later.
  • Anthracyclines (doxorubicin, daunorubicin): cardiomyopathy that grows with the cumulative dose, red urine, and severe tissue injury if the drug leaks out of the vein.
  • Antimetabolites: methotrexate (mucositis, kidney injury, liver damage; leucovorin rescue; held in fluid collections), cytarabine (high-dose: cerebellar ataxia and conjunctivitis), fludarabine (deep T-cell suppression, Pneumocystis, autoimmune haemolysis).
  • Microtubule drugs (vincristine, vinblastine) and proteasome inhibitors (bortezomib): peripheral neuropathy; vincristine also causes constipation and ileus and is fatal if given into the spinal fluid.
  • Others: cisplatin (kidney, hearing, low magnesium), bleomycin (lung fibrosis), asparaginase (pancreatitis, clots, low fibrinogen, allergy), thalidomide and lenalidomide (venous clots, birth defects), tretinoin and arsenic (differentiation syndrome; arsenic lengthens the QT).

How it is done (and why)

  1. Before treatment: count, kidney and liver tests, heart scan before anthracyclines, hepatitis B and HIV tests, fertility counselling, pregnancy test.
  2. Prevent the predictable: antiemetics, mesna with ifosfamide or high-dose cyclophosphamide, tumour-lysis and infection prophylaxis.
  3. Check identity and route twice: vinca alkaloids are given only intravenously, in a minibag, never near intrathecal drugs.
  4. During treatment: counts before each cycle; teach patients that fever during the nadir is an emergency.
  5. Track cumulative exposure for drugs with a lifetime limit (anthracyclines, bleomycin) and repeat heart imaging as the protocol requires.
  6. After treatment: long-term follow-up for heart failure, second cancers, infertility, thyroid and lung problems, often for life after childhood cancer.

Each class and its signature harm

ClassExamplesSignature harmHow it is prevented or watched
Alkylating agentsCyclophosphamide, ifosfamide, melphalan, busulfanHaemorrhagic cystitis, infertility, second MDS/AML after 5–10 yearsMesna and fluids, fertility preservation, long-term counts
Anthracyclines and other topoisomerase II drugsDoxorubicin, daunorubicin, etoposideCardiomyopathy (anthracyclines); second AML within a few yearsEchocardiogram, cumulative dose limit, dexrazoxane in selected patients
AntimetabolitesMethotrexate, cytarabine, fludarabineMucositis and kidney injury; cerebellar toxicity; deep immunosuppressionDrug levels and leucovorin rescue; neurological checks; Pneumocystis prophylaxis and irradiated blood
Microtubule drugsVincristine, vinblastineNeuropathy, constipation; fatal if intrathecalNeurological review, bowel care, strict route checks
Platinum and bleomycinCisplatin, carboplatin, bleomycinKidney and hearing damage; lung fibrosisHydration and magnesium; hearing tests; lung function, caution with high oxygen
AsparaginaseAsparaginasePancreatitis, clots, low fibrinogen, allergy, high glucoseAmylase or lipase, fibrinogen and glucose; watch for clots

Risks and precautions

  • Breathlessness in a lymphoma survivor treated with an anthracycline years earlier may be heart failure; ask about past chemotherapy.
  • Blood in the urine during cyclophosphamide or ifosfamide treatment suggests haemorrhagic cystitis; in transplant patients a virus (BK) can cause the same picture.
  • Patients who received fludarabine, bendamustine or a purine analogue need irradiated blood components to prevent transfusion-associated graft-versus-host disease.
  • Rituximab and other B-cell drugs can reactivate hepatitis B: test before treatment and give antiviral prophylaxis when markers are positive.
  • Bleomycin-exposed patients can develop lung injury with high oxygen concentrations during later surgery; tell the anaesthetist.

Monitoring and next step

  • Full count before each cycle and at the expected nadir if symptoms appear.
  • Creatinine, electrolytes including magnesium, and liver tests; methotrexate levels after high-dose treatment.
  • Echocardiogram or other heart imaging before and during anthracycline treatment.
  • Hepatitis B surface antigen and core antibody, and HIV, before immunochemotherapy.
  • Fibrinogen, glucose and pancreatic enzymes during asparaginase; urine for blood during alkylating agents.

Common traps

  • Waiting for symptoms to check the heart on anthracyclines: damage is often silent until it is advanced, so imaging is planned
  • Thinking vincristine is safe because it hardly lowers the counts: its harm is to nerves and bowel, and intrathecal vincristine is fatal
  • Giving high-flow oxygen freely after bleomycin: high oxygen can trigger or worsen bleomycin lung injury
  • Giving methotrexate to a patient with ascites or a pleural effusion: the drug pools in the fluid and leaks out slowly, prolonging toxicity
  • Blaming every late blood problem on relapse: a second MDS or AML after alkylating agents or topoisomerase II drugs is a separate disease

Test yourself

Think of the answer, then tap the question to see it.

A woman receiving cyclophosphamide for lymphoma develops painful visible blood in the urine. Which mechanism explains it, and how is it prevented?

Acrolein, a breakdown product concentrated in the urine, injures the bladder lining; hydration and mesna, which binds acrolein, help prevent it.

A 30-year-old treated for Hodgkin lymphoma at 15 now has breathlessness and leg swelling. Which past drug class should be asked about first, and why?

Anthracyclines: they cause a cumulative, dose-related cardiomyopathy that can appear years after treatment.

Why is vincristine always given intravenously in a minibag and kept away from intrathecal drugs?

Vincristine injected into the spinal fluid destroys the nervous system and is almost always fatal; separating routes prevents this known error.

Which drug class explains AML appearing six years after treatment for myeloma, and how is it different from relapse?

Alkylating agents such as melphalan cause therapy-related MDS/AML, often with chromosome 5 or 7 loss; it is a new, usually high-risk disease, not the old cancer returning.

Add to my cards (4)

Elsewhere in DurgiPedia

Connections

← All of haematology

Educational content; it does not replace assessment by a doctor or your institution's protocols. It contains no doses.

Sources: Chemotherapy to Treat Cancer (National Cancer Institute (NCI), 2026); Side Effects of Cancer Treatment (National Cancer Institute (NCI), 2026); Anthracycline Toxicity (StatPearls (NCBI Bookshelf), 2024); Methotrexate (StatPearls Publishing (NCBI Bookshelf), 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.